DDInter268 DDInter253
Calcitriol is an active metabolite of vitamin D with 3 hydroxyl (OH) groups and is commonly referred to as 1,25-dihydroxycholecalciferol, or 1alpha,25-dihydroxyvitamin D<sub>3</sub>, 1,25-dihydroxyvitamin D<sub>3</sub>. It is produced in the body after series of conversion steps of 7-dehydrocholesterol from exposure to UV light. 7-dehydrocholesterol is converted to (vitamin D3) in the skin, which is then converted to in the liver and kidneys. undergoes hydroxylation to form calcitriol via 1α-hydroxylase (CYP27B1) activity. Calcitriol is considered to be the most potent metabolite of vitamin D in humans. Renal production of calcitriol is stimulated in response to PTH
Burosumab (KRN23) is an entirely human monoclonal IgG1 antibody that binds excess fibroblast growth factor 23 (FGF23) and has been successfully tested in clinical trials in children with X-linked hypophosphatemic rickets . The U.S. Food and Drug Administration approved Crysvita (burosumab) in April 2018. This is the first drug approved to treat adults and children ages 1 year and older with X-linked hypophosphatemia (XLH), which is a rare, inherited form of rickets. X-linked hypophosphatemia causes low circulating levels of phosphorus in the blood. It causes impaired bone growth and development in children and adolescents and issues with bone mineralization throughout a patient’s life . XLH is a serious disease which affects about 3,000 children and 12,000 adults in the United States. Most children with XLH suffer from bowed or bent legs, short stature, bone pain and severe dental pain. Some adults with this condition suffer from persistent, unrelenting discomfort and complications, such as joint pain, impaired mobility, tooth abscesses and hearing loss .
Calcitriol {u} (Compound) resembles {v} (Compound) Paricalcitol
Paricalcitol {u} may lead to a major life threatening interaction when taken with {v} Burosumab
Calcitriol {u} (Compound) resembles {v} (Compound) Paricalcitol
Paricalcitol {u} may lead to a major life threatening interaction when taken with {v} Doxercalciferol
Doxercalciferol {u} may lead to a major life threatening interaction when taken with {v} Burosumab
Calcitriol {u} (Compound) resembles {v} (Compound) Paricalcitol
Paricalcitol {u} may lead to a major life threatening interaction when taken with {v} Calcifediol
Calcifediol {u} may lead to a major life threatening interaction when taken with {v} Burosumab
Calcitriol {u} (Compound) resembles {v} (Compound) Ergocalciferol
Ergocalciferol {u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v} Paricalcitol
Paricalcitol {u} may lead to a major life threatening interaction when taken with {v} Burosumab
Calcitriol {u} (Compound) resembles {v} (Compound) Calcipotriol
Calcipotriol {u} (Compound) resembles {v} (Compound) Paricalcitol
Paricalcitol {u} may lead to a major life threatening interaction when taken with {v} Burosumab
Calcitriol {u} (Compound) resembles {v} (Compound) Calcipotriol
Calcipotriol {u} (Compound) resembles {v} (Compound) Calcifediol
Calcifediol {u} may lead to a major life threatening interaction when taken with {v} Burosumab
Calcitriol {u} (Compound) resembles {v} (Compound) Cholecalciferol
Cholecalciferol {u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v} Calcifediol
Calcifediol {u} may lead to a major life threatening interaction when taken with {v} Burosumab
Calcitriol {u} (Compound) binds {v} (Gene) CYP24A1
CYP24A1 {u} (Gene) is bound by {v} (Compound) Paricalcitol
Paricalcitol {u} may lead to a major life threatening interaction when taken with {v} Burosumab
Calcitriol {u} (Compound) palliates {v} (Disease) chronic kidney failure
chronic kidney failure {u} (Disease) is palliated by {v} (Compound) Paricalcitol
Paricalcitol {u} may lead to a major life threatening interaction when taken with {v} Burosumab
Calcitriol {u} (Compound) is included by {v} (Pharmacologic Class) Cholecalciferol
Cholecalciferol {u} (Pharmacologic Class) includes {v} (Compound) Paricalcitol
Paricalcitol {u} may lead to a major life threatening interaction when taken with {v} Burosumab
Calcitriol (Compound) resembles Paricalcitol (Compound) and Paricalcitol may lead to a major life threatening interaction when taken with Burosumab
Calcitriol (Compound) resembles Paricalcitol (Compound) and Paricalcitol may lead to a major life threatening interaction when taken with Doxercalciferol and Doxercalciferol may lead to a major life threatening interaction when taken with Burosumab
Calcitriol (Compound) resembles Paricalcitol (Compound) and Paricalcitol may lead to a major life threatening interaction when taken with Calcifediol and Calcifediol may lead to a major life threatening interaction when taken with Burosumab
Calcitriol (Compound) resembles Ergocalciferol (Compound) and Ergocalciferol (Compound) resembles Paricalcitol (Compound) and Ergocalciferol may lead to a major life threatening interaction when taken with Paricalcitol and Paricalcitol may lead to a major life threatening interaction when taken with Burosumab
Calcitriol (Compound) resembles Calcipotriol (Compound) and Calcipotriol (Compound) resembles Paricalcitol (Compound) and Paricalcitol may lead to a major life threatening interaction when taken with Burosumab
Calcitriol (Compound) resembles Calcipotriol (Compound) and Calcipotriol (Compound) resembles Calcifediol (Compound) and Calcifediol may lead to a major life threatening interaction when taken with Burosumab
Calcitriol (Compound) resembles Cholecalciferol (Compound) and Cholecalciferol (Compound) resembles Calcifediol (Compound) and Cholecalciferol may lead to a major life threatening interaction when taken with Calcifediol and Calcifediol may lead to a major life threatening interaction when taken with Burosumab
Calcitriol (Compound) binds CYP24A1 (Gene) and CYP24A1 (Gene) is bound by Paricalcitol (Compound) and Paricalcitol may lead to a major life threatening interaction when taken with Burosumab
Calcitriol (Compound) palliates chronic kidney failure (Disease) and chronic kidney failure (Disease) is palliated by Paricalcitol (Compound) and Paricalcitol may lead to a major life threatening interaction when taken with Burosumab
Calcitriol (Compound) is included by Cholecalciferol (Pharmacologic Class) and Cholecalciferol (Pharmacologic Class) includes Paricalcitol (Compound) and Paricalcitol may lead to a major life threatening interaction when taken with Burosumab